Compare Moderna, Inc. (MRNA) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Nuscale Power Corporation — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Nuscale Power Corporation trades at $7.2 (market cap $3.00B). The key difference: Moderna, Inc. is far larger — about 26.2× Nuscale Power Corporation's market cap, and Moderna, Inc. is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Nuscale Power Corporation for 29 Days on average.
| MRNA | SMR | |
|---|---|---|
Market Cap | $78.65B | $3.00B |
Volume | 37,373,437 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $203.46 | $53.43 |
52-Week Low | $22.36 | $7.32 |
Typical Hold Time | 59 Days | 29 Days |
Enterprise Value | $74.80B | $1.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
NuScale Power (SMR) trades at $7.32, down 4.56% today, amid bearish technical signals and challenging fundamentals. The company reported significant losses with a net income margin of -3,888.7% in 2026 and negative cash flow from operations. Despite analyst consensus pointing to a $11.25 price target with 50% buy ratings, recent news highlights investor concerns including an ongoing legal investigation announced by Pomerantz Law Firm on October 1, 2026.
The stock faces substantial execution risks as it burns cash to commercialize small modular reactor technology. While nuclear energy presents long-term growth potential, SMR's path to profitability remains uncertain given current financial metrics and competitive pressures from established players like GE Vernova. The wide analyst target range ($6-$16) reflects divided sentiment on the company's prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
